(Date:5/17/2013)... occurs when the transplant recipient,s immune system identifies the ... was previously thought that T cells, the immune cells ... known as chemokines in order to migrate to the ... of Clinical Investigation , Fadi Lakkis and colleagues at ... chemokine stimulation of T cells is not required for ...
(Date:5/17/2013)... The new Public-Private Partnership (PPP) in ... association’s recent annual meeting drew praise from community leaders ... who called the action “a huge step forward … ... European innovation.” , The Board of Stakeholders voted to ... PPP at its 29 April meeting in Brussels, which ...
(Date:5/17/2013)... PALO ALTO, Calif. , May 17, 2013 ... that it has achieved 50% enrollment of the ... trial to evaluate the safety and preliminary efficacy ... Progenitor Cells) therapy for Knee Osteoarthritis (KOA). To ... Effect (SAE) reported. The Phase I ...
(Date:5/17/2013)... May 17, 2013 Insero Health, Inc., a company ... epilepsy and related neurological disorders, is today reporting top-line ... compound INS001 in patients with drug-resistant epilepsy. The data ... Trials (AED) Xll meeting by Dr. Steven ... of Insero,s Scientific Advisory Board. In this study, INS001 ...
Breaking Biology Technology:SPIE Joins in Praise for ‘Huge Step Forward’ for Innovation R&D Enabled by Photonics21 Actions 2SPIE Joins in Praise for ‘Huge Step Forward’ for Innovation R&D Enabled by Photonics21 Actions 3Cellular Biomedicine Group Achieves 50% Enrollment Milestone in Phase I Clinical Trial for Knee Osteoarthritis 2Insero Health Reports Positive Data on Phase I Trial of Novel Therapy for Drug-resistant Epilepsy 2